Mantle cell lymphoma (MCL) is a unique type of non-Hodgkin lymphoma characterized by the overexpression of cyclin D1. MCL patients typically live for years but experience multiple relapses. Acalabrutinib is a novel second-generation oral Bruton tyrosine kinase inhibitor approved by the US Food and Drug Administration for relapsed MCL based on a clinical trial demonstrating an overall response rate of 81%. It provides a valuable new treatment option for MCL patients and is now being tested upfront.
Keyphrases
- end stage renal disease
- clinical trial
- newly diagnosed
- ejection fraction
- chronic kidney disease
- drug administration
- peritoneal dialysis
- prognostic factors
- acute lymphoblastic leukemia
- randomized controlled trial
- acute myeloid leukemia
- cell proliferation
- patient reported outcomes
- risk assessment
- human health
- signaling pathway
- combination therapy
- phase ii